Seeking Alpha

More on GlaxoSmithKline's (GSK) Q2: Net profit slides 16%. The company says it will "likely see...

More on GlaxoSmithKline's (GSK) Q2: Net profit slides 16%. The company says it will "likely see some impact to performance in China as a result of the current investigation" but notes it is "too early to quantify the extent." Management remains cautious on Europe (where pharmaceutical and vaccine sales were flat) as GSK expects "austerity pressures to continue." The company will remain focused on "targeted divestments of non-core assets" and sees core EPS growth of 3-4% for FY13. Shares flat in premarket trading.(PR)

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs